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ABSTRACT
A recent in vitro study suggested that CYP2C8 is essential in the
metabolism of desloratadine, an H1 receptor antagonist. If the
proposed biotransformation mechanism takes place in vivo in
humans, desloratadine could serve as a selective CYP2C8 probe
substrate in drug-drug interaction studies. Glucuronide metabo-
lites of clopidogrel and gemfibrozil act as time-dependent inhibitors
ofCYP2C8, but they havenot beencomparedclinically.Weconducted
a randomized crossover study in 11 healthy subjects to character-
ize the involvement of CYP2C8 in desloratadine metabolism and to
compare theCYP2C8 inhibitory strengthof clopidogrel (300 and 75mg
on two following days) with that of gemfibrozil (600mgBID for 5 days).
Compared with placebo (control), clopidogrel increased the area
under the plasma concentration-time curve (AUC0–‘) and peak
plasma concentration (Cmax) of desloratadine to 280% (P = 33 10
27)
and 165% (P = 0.0006), respectively. The corresponding increases by
gemfibrozil were to 462% (P = 4 3 1027) and 174% (P = 0.0006).
Compared with placebo, clopidogrel and gemfibrozil decreased
3-hydroxyloratadine AUC0–71h to 52% (P = 5 3 10
25) and 6% (P =
2 3 1028), respectively. Moreover, the 3-hydroxydesloratadine:
desloratadine AUC0–71 h ratios were 21% (P = 73 10
210) and 1.7%
(P = 8 3 10211) of control during the clopidogrel and gemfibrozil
phases. Our results confirm that CYP2C8 plays a critical role in
the formation of 3-hydroxydesloratadine in humans, making
desloratadine a potential CYP2C8 probe substrate. Furthermore,
the findings corroborate the previous estimates that clinically
relevant doses of clopidogrel cause strong CYP2C8 inhibition,
whereas those of gemfibrozil almost completely inactivate the
enzyme in humans.
Introduction
Desloratadine is a potent, nonsedating H1 histamine receptor
antagonist indicated for symptomatic relief of urticaria and allergic
rhinitis (https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/
021165s017,021300s014,021312s015,021563s003lbl.pdf; Henz, 2001).
It has linear pharmacokinetics in the 5- to 20-mg dose range, is 82%–
87% bound to plasma proteins, and has a terminal half-life (t1/2) of
about 21–27 hours (Henz, 2001; Murdoch et al., 2003; Molimard
et al., 2004). It is extensively metabolized, and its major metabolite
is 3-hydroxydesloratadine, which is further glucuronidated to 3-
hydroxydesloratadine-O-glucuronide (Molimard et al., 2004). A recent
in vitro study suggested a central role for cytochrome P450 2C8 (CYP2C8)
in the formation of the 3-hydroxy metabolite, involving initial N-
glucuronidation of desloratadine followed by CYP2C8-dependent
oxidation of the N-glucuronide and subsequent rapid deconjugation
(Fig. 1) (Kazmi et al., 2015a). The proposed CYP2C8-selective metab-
olism and the benign safety profile could make desloratadine a practical
CYP2C8 probe substrate in drug-drug interaction (DDI) studies (Prenner
et al., 2006).
The acyl-b-D-glucuronide metabolite of the antiplatelet agent clopi-
dogrel and the 1-O-glucuronide metabolite of the fibric acid derivative
gemfibrozil act as mechanism-based inhibitors of CYP2C8 (Ogilvie
et al., 2006; Tornio et al., 2014; Backman et al., 2016). Accordingly,
in humans, clopidogrel and gemfibrozil have significantly increased
the exposure to several CYP2C8 substrates such as cerivastatin, repagli-
nide, pioglitazone, montelukast, and dasabuvir (Backman et al., 2002,
2016; Niemi et al., 2003; Jaakkola et al., 2005; Karonen et al., 2010;
Tornio et al., 2014; Itkonen et al., 2016, 2018, 2019). Recently, both
clopidogrel and gemfibrozil were suggested as model CYP2C8 inhibitors
for DDI studies in the FDA Draft Guidance for Clinical Drug Interaction
Studies (https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf).
The CYP2C8-inhibitory strength of clopidogrel, however, has not been
directly compared with that of gemfibrozil in a clinical setting.
Glucuronide metabolites have generally been regarded as relatively
stable and physiologically inactive compounds, but owing to the reactivity
of acyl glucuronides as well as their ability to act as perpetrators in drug
interactions, these presumptions have been challenged by Ogilvie et al.
(2006), Regan et al. (2010), Tornio et al. (2014), and Backman et al. (2016).
Apart from the ability of CYP2C8 to reactivate glucuronides of gemfibrozil,
clopidogrel, and deleobuvir, leading to CYP2C8 inactivation, several
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glucuronides of xenobiotics and steroid hormones, including those of
diclofenac, licofelone, estradiol, and desloratadine, have been shown
to undergo CYP2C8-mediated oxidation in vitro (Kumar et al., 2002;
Delaforge et al., 2005; Albrecht et al., 2008; Backman et al., 2016).
However, research on pharmacological activity and qualities of glucu-
ronides is still scarce, and their potential to act as DDI perpetrators has not
been routinely screened during drug development. Moreover, clinical
data demonstrating the role of CYP2C8 in the metabolism of glucuronide
compounds is lacking.
The primary objectives of the present clinical study were to examine
the role of CYP2C8 in desloratadine metabolism and evaluate the
applicability of desloratadine as a CYP2C8 probe substrate. Moreover,
we aimed to compare head-to-head the CYP2C8 inhibitory effects of the
typical clinically used doses of clopidogrel and gemfibrozil in vivo in
humans.
Materials and Methods
Subjects and Study Design. Twelve subjects were recruited for the study,
but one of them withdrew from the study after the second phase for personal
reasons. Eleven healthy nonsmoking volunteers (six women, five men; age
range, 20–29 years; body mass index range, 18.6–27.3 kg/m2) participated in
the study after giving written informed consent. Their health was confirmed
by medical history, clinical examination, and routine laboratory tests before
entering the study. All participants had normal blood platelet counts and hemoglobin
values. None of the subjects used oral contraceptives or other continuous medication.
The study protocol was approved by the Coordinating Ethics Committee of the
Helsinki and Uusimaa Hospital District (record number 296/13/03/00/2015), and
the Finnish Medicines Agency Fimea (EudraCT number 2015-000368-32). In a
randomized, placebo-controlled, three-phase crossover study, the subjects ingested
as pretreatment either gemfibrozil on days 1–5 [600 mg twice daily (BID), at 8 AM
and 8 PM; Lopid; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany],
clopidogrel on days 3–5 (300mg at 8AMonday 3 followed by 75mg on days 4–5;
Plavix, Sanofi-Aventis, Paris, France), or placebo on days 1–5 (twice daily at 8 AM
and 8 PM; placebo tablets, University Pharmacy, Helsinki, Finland). Between
the phases, there was a wash-out period of at least 3 weeks. On day 3, 5 mg of
desloratadine (Aerius 5-mg tablet; Merck Sharp & Dohme Ltd, Hoddeson,
United Kingdom) was administered at 9 AM with 150 ml water. On the days of
desloratadine ingestion, the volunteers had fasted overnight, and a standard
warmmeal was served 3 hours and snacks 7 and 10 hours after the administration
of desloratadine. The use of grapefruit products was not allowed for 1 week
before and during the study, and the use of other drugs from 1 week before to
1 week after the study. The subjects experienced no significant or unexpected
adverse effects.
Sampling. Timed venous blood samples (4 or 9 ml) were drawn before the
administration of pretreatment on the morning of day 3, and 5 minutes before
and 0.5, 1, 2, 3, 4, 5, 7, 9, 11, 23, 47, and 71 hours after the administration of
desloratadine. The blood samples were collected into tubes containing EDTA,
which were placed on ice immediately after sampling. Plasma was separated
within 30 minutes and stored at 270C until analysis. The samples for the
determination of clopidogrel and its metabolites were treated with 2-bromo-39-
methoxyacetophenone within 30 seconds of blood sample collection in whole
blood EDTA samples, to derivatize the active metabolite of clopidogrel, as
previously described (Holmberg et al., 2014).
Determination of Plasma Desloratadine and Its Metabolites. Prior to
quantification by liquid chromatography–tandem mass spectrometry (LC-MS/MS),
the plasma samples were purified by solid phase extraction using Strata-X Polymeric
Reversed Phase, 96-Well Plate (10 mg/well; Phenomenex, Torrance, CA). In
brief, the samples (120 ml) were mixed with 100 ml of internal standard solution
containing desloratadine-d5 and 3-hydroxydesloratadine-d4 (5 ng/ml) in 50 mM
ammonium acetate (pH 4.7), and drawn through the preconditioned extraction
plate. The wells were then washed with 10% methanol and the analytes were
eluted with methanol containing 1% formic acid. Finally, the sample extracts
were dried using a centrifugal evaporator (GeneVac; Thermo Fisher Scientific,
Waltham, MA) and reconstituted in 100 ml of mobile phase starting composition.
The analytes were separated on a Kinetex C18 XB column (2.6-mm particle size,
2.1  100-mm internal diameter; Phenomenex) using a Nexera 2 ultra-high-
performance liquid chromatography system (Shimadzu, Kyoto, Japan). The
mobile phase consisted of 0.02% formic acid in 5 mM ammonium acetate (mobile
Fig. 1. The proposed biotransformation
pathways and the chemical structures of
desloratadine and its 5-hydroxy, 6-hydroxy,
N-glucuronide, 3-hydroxy, and 3-hydroxy-O-
glucuronide metabolites (Kazmi et al., 2015a).












phase A) and acetonitrile (mobile phase B), and a solvent gradient was adopted as
follows for the total run time of 11 minutes: 3 minutes at 20% B; a linear increase
from 20%B to 63%B over 3 minutes; 1 minute at 90%B; 4 minutes equilibration
at 20% B. The flow rate and the column temperature were maintained at
300 ml/min and 30C, and an aliquot of 2 ml was injected into the system.
A Sciex 5500 Qtrap tandem mass spectrometer (Sciex, Toronto, Ontario,
Canada) interfaced with an electrospray ion source was used for the mass
spectrometric detection. The mass spectrometer was operated in the positive-
polarity multiple-reaction mode and the Q1 and Q3 quadrupoles were set at
unit mass resolution. The mass transitions (m/z) 311 to 259, 327 to 275, and
503 to 327 were selected for desloratadine, 3-hydroxydesloratadine, and
3-hydroxydesloratadine N-glucuronide, respectively. The lower limit of
quantification (LLQ) for desloratadine and 3-hydroxydesloratadine were
0.05 and 0.025 ng/ml, respectively. A signal-to-noise ratio of 3:1 was used as a
limit of detection for 3-hydroxydesloratadine N-glucuronide, and the quanti-
ties were given in arbitrary units (units per milliliter) relative to the ratio of the
peak heights of the 3-hydroxydesloratadine N-glucuronide to the internal
standard (3-hydroxydesloratadine-d4). The day-to-day coefficients of varia-
tion (CV) were 6.0% (0.2 ng/ml), 2.6% (2.0 ng/ml), and 4.6% (20 ng/ml) for
desloratadine, and 4.2% (0.1 ng/ml), 2.1% (1.0 ng/ml), and 3.5% (10 ng/ml)
for 3-hydroxydesloratadine.
Determination of Plasma Gemfibozil and Gemfibrozil-1-O-Glucuronide.
The plasma gemfibrozil and gemfibrozil-1-O-glucuronide were purified using a
simple protein precipitation with acetonitrile (1:3) containing the correspond-
ing deuterium-labeled internal standards, gemfibrozil-d6, and gemfibrozil-1-O-
glucuronide-d6 (0.5 mg/ml). The plasma extract was then further diluted with
water and introduced to the Sciex 5500 Qtrap LC-MS/MS System. The
chromatographic separation of the analytes was carried out on a Kinetex C18
column (75  2.1-mm internal diameter, 2.6-mm particle size; Phenomenex)
using 2 mM ammonium acetate (pH 4) and acetonitrile (mobile phase B). The
following gradient conditions were applied: 1 minute at 20% B on hold, then
a linear increase from 20%B to 90%B over 4minutes followed by a re-equilibration
step back to the initial conditions (20% B). The characteristic negative multiple
reactionmode ion transitions,m/z 249 to 121 andm/z 425 to 121, were used for the
quantification of gemfibrozil and gemfibrozil-1-O-glucuronide. The lower LLQ
for both analytes was 0.05mg/ml and the day-to-day coefficients of variation were
below 10% at relevant concentrations.
Determination of Plasma Clopidogrel and Its Metabolites. The plasma
clopidogrel and its metabolites were measured using a Sciex 5500 Qtrap
LC-MS/MS system as previously described (Holmberg et al., 2014; Tornio
et al., 2014; Itkonen et al., 2015). The LLQs were 0.05 ng/ml for clopidogrel
and clopidogrel active cis-5-thiol metabolite, 20 ng/ml for clopidogrel carboxylic
acid, and 25 ng/ml for clopidogrel acyl-b-D-glucuronide. The day-to-day precision
values for all compounds were below 15% (expressed as CV%) and the accuracy
was within 615%, except for LLQ, for which both precision and accuracy were
within 620%.
Pharmacokinetics. The peak plasma concentration (Cmax), time toCmax (tmax),
area under the plasma concentration-time curve from time 0–71 hours (AUC0–71 h),
AUC0–‘ (when appropriate), and t1/2 were calculated for desloratadine and its
metabolites by standard noncompartmental methods using Phoenix WinNonlin,
version 6.4 (Certara, Princeton, NJ). In the gemfibrozil phase, the concentrations
of 3-hydroxydesloratadine and desloratadine 3-hydroxy-O-glucuronide were under
the LLQ at several time points after the administration of desloratadine. To
calculate theAUC0–71 h, the aforementioned concentration values lower than LLQ
were replaced with values equal to half of the LLQ. For gemfibrozil, clopidogrel,
and their metabolites, Cmax, tmax, t1/2, and AUC0–12 h were calculated.
Genotyping. Buffy coats were prepared from 9 ml of whole-blood EDTA
samples after plasma separation. Genomic DNAwas extracted from the buffy coats
using the Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research automated
nucleic acid extraction system (Promega, Madison, WI). The participants were
genotyped for the CYP2C8*2 (rs11572103), *3 (rs10509681 and rs11572080),
and *4 (rs1058930) alleles with commercially available or custom TaqMan assays
with OpenArray technology on a QuantStudio 12K Flex real-time PCR system
(Life Technologies/Thermo Fisher Scientific, Carlsbad, CA).
Two of the subjects had the CYP2C8*1/*3 genotype, and two had the
CYP2C8*1/*4 genotype, whereas the others had the CYP2C8*1/*1 genotype.
There were no apparent genotype-dependent differences in the pharmacokinetics
of desloratadine or its metabolites (data not shown). Owing to the small sample
size and lack of subjects with desloratadine “poor metabolizer” phenotype,
UGT2B10 was not included in the genotyping panel.
Drug-Drug Interaction Predictions. Inhibition of CYP2C8 by clopidogrel
acyl-b-D-glucuronide and gemfibrozil 1-O-glucuronide was predicted using
mechanism-based in vitro inhibition values from the literature with a mechanistic
static model according to following equation:
Activity remaining ¼ kdeg
kdeg þ kinactIKIþI
where kdeg is the rate constant of hepatic P450 degradation in the absence of the
inhibitor, kinact is the maximum inactivation rate, I is the unbound inhibitor
concentration at the enzyme site, andKI is the inhibitor concentration needed to
cause half of kinact. A half-life of 22 hours for CYP2C8 was used, corresponding
to kdeg of 0.000525 (Backman et al., 2009). The kinact values were 2.82 1/min and
0.21 1/min, and KI values were 9.9 mM and 20 mM for clopidogrel acyl-b-D-
glucuronide and gemfibrozil 1-O-glucuronide, respectively (Ogilvie et al., 2006;
Tornio et al., 2014).
Statistical Analysis. On the basis of our previous drug interaction studies,
twelve subjects were estimated to be adequate to detect a 30% change in the
AUC of the victim drug and its main metabolite between the placebo (control)
and clopidogrel and gemfibrozil phases, with a power of at least 80% (a level
5%). The results are expressed as geometric means and geometric mean ratios
with geometric CV or 90% confidence intervals (CIs) unless stated otherwise.
Logarithmic transformation was used for pharmacokinetic variables, except
tmax, before statistical analysis. The pharmacokinetic variables were compared
by repeated-measures analysis of variance with treatment phase as a within-
subjects factor, followed by pairwise comparisons with Bonferroni-corrected
analysis of variance. The tmax data were compared using the Wilcoxon signed
rank test. Correlations between the fold-change in desloratadine AUC and the
3-hydroxydesloratadine:desloratadine AUC0–71h ratio between clopidogrel and
gemfibrozil phases were quantified as Pearson’s correlation coefficients. P-values
below 0.05 were considered statistically significant. Statistical analyses were
performed using SPSS Statistics for Windows version 22.0 (IBM Corporation,
Armonk, NY).
Results
Effect of Clopidogrel on Parent Desloratadine. Compared with
placebo (control), clopidogrel increased desloratadine AUC0–‘ to 280%
(P = 3  1027; 90% CI 232%–338%). In addition, the Cmax of
desloratadine was increased to 165% (P = 0.0006; 90%CI 133%–204%)
and its t1/2 prolonged from 17 to 26 hours (ratio to control 150%; P =
0.0003; 90% CI 130%–180%) by clopidogrel (Fig. 2; Table 1).
Effect of Clopidogrel on 3-Hydroxydesloratadine. Clopidogrel
decreased the 3-hydroxydesloratadine AUC0–‘ to 74% (P = 5  1025;
90% CI 69%–80%) of control. Moreover, in the clopidogrel phase, the
3-hydroxydesloratadine:desloratadine AUC0–71 h ratio was 21% (P =
7  10210; 90% CI 18%–24%) of that during the control phase.
Compared with placebo, clopidogrel decreased 3-hydroxydesloratadine
Cmax to 30% (P = 1 1027; 90% CI 25%–37%), and prolonged the t1/2
from 25 to 51 hours (ratio to control 200%; P = 2  1025; 90% CI
170%–240%).
Effect of Clopidogrel on 3-Hydroxydesloratadine-O-Glucuronide.
During the clopidogrel phase, the AUC0–‘ of 3-hydroxydesloratadine-
O-glucuronide was 71% (P = 0.0008; 90% CI 62%–81%) of that in the
placebo phase. Furthermore, the Cmax of 3-hydroxydesloratadine-O-
glucuronide was decreased to 37% (P = 3  1027; 90% CI 31%–45%)
and its t1/2 prolonged from 19 to 35 hours (P = 2 1025; 90%CI 163%–
218%) by clopidogrel, compared with those in the control phase.
Effect of Gemfibrozil on Parent Desloratadine. Compared with
placebo (control), gemfibrozil increased desloratadine AUC0–‘ to 462%
(P = 4  1027; 90% CI 346%–616%). The Cmax of desloratadine was
increased to 174% (P = 0.0006; 90%CI 137%–221%) of control and t1/2
prolonged from 17 to 39 hours (ratio to control 220%; P = 3  1028;
90% CI 200%–250%) by gemfibrozil (Fig. 2; Table 1).












Fig. 2. The effect of clopidogrel (300 mg on day 3, followed by 75 mg on days 4 and 5) and gemfibrozil (600 mg twice daily on days 1–5) on the plasma concentrations of
desloratadine (A), and its 3-hydroxy (B), and 3-hydroxy-O-glucuronide (C) metabolites. On day 3, desloratadine 5 mg was administered to 11 healthy volunteers 1 hour after
the morning dose of each pretreatment. Data are presented as geometric means with 90% confidence intervals. For clarity, some error bars have been omitted. Insets depict
the same data on semilogarithmic scale.












Effect of Gemfibrozil on 3-Hydroxydesloratadine. During the
gemfibrozil phase, the concentrations of 3-hydroxydesloratadine
were very low, and the 3-hydroxydesloratadine AUC0–71 h and
3-hydroxydesloratadine:desloratadine AUC0–71 h ratios were 6% (P =
2  1028; 90% CI 4%–9%) and 1.7% (P = 8  10211; 90% CI 1.3%–
2.4%) of control, respectively. Gemfibrozil decreased the Cmax of
3-hydroxydesloratadine to 4% of control (P = 8  10210; 90% CI
3%–5%). Owing to the extremely low 3-hydroxydesloratadine concen-
trations, its t1/2 could not be reliably determined inmost of the subjects in
the gemfibrozil phase.
Effect of Gemfibrozil on 3-Hydroxydesloratadine-O-Glucuronide.
In the gemfibrozil phase, the AUC0–71 h of 3-hydroxydesloratadine-
O-glucuronide was 6% (P = 7 1028; 90% CI 4%–10%) and its Cmax
was 4% (P = 3  1028; 90% CI 2%–6%) of that in the placebo phase. In
addition, the tmax of 3-hydroxydesloratadine-O-glucuronide was prolonged
from 9.0 to 11.0 hours (P = 0.03). As with 3-hydroxydesloratadine, the
plasma concentrations of 3-hydroxydesloratadine-O-glucuronide were too
low for accurate calculation of its t1/2 during the gemfibrozil phase.
Head-to-Head Comparison of the Effects of Clopidogrel and
Gemfibrozil. In general, gemfibrozil’s effect on desloratadine pharma-
cokinetics was stronger than clopidogrel’s (Fig. 2). By gemfibrozil,
desloratadine AUC0–‘ was 165% (P = 2 1025; 90% CI 142%–191%)
of that by clopidogrel. Moreover, 3-hydroxydesloratadine AUC0–71h was
12% (P = 1 1028; 90% CI 9%–16%) and the 3-hydroxydesloratadine:
desloratadine AUC0–71 h ratio was 8% (P = 7 10210; 90%CI 7%–11%),
compared with those in the clopidogrel phase. Additionally, in the
gemfibrozil phase, the AUC0–71 h of 3-hydroxydesloratadine-O-
glucuronide was 11% (P = 1  1028; 90% CI 9%–15%) of that in
the clopidogrel phase. There was a significant (Pearson two-tailed,
P = 0.002; R2 = 0.80) correlation between the fold-change in desloratadine
AUC0–‘ caused by clopidogrel and that by gemfibrozil (Fig. 2C).
Pharmacokinetic Variables of Clopidogrel and Gemfibrozil. The
Cmax of clopidogrel and gemfibrozil, as well as their metabolites, were
reached 1–3 hours after their ingestion (Table 2), i.e., around or soon
after the time of desloratadine administration. Therewere 50- and 20-fold
interindividual variations in parent clopidogrel Cmax and AUC0–12h,
respectively. In addition, a 3- to 4-fold variation was observed in those of
the active cis-5-thiol, carboxylic acid, and acyl-b-D-glucuronide metab-
olites of clopidogrel. The variation in the pharmacokinetic variables of
gemfibrozil and its 1-O-glucuronide metabolite was smaller, only up to
2-fold. Consistent with previous DDI studies between clopidogrel
or gemfibrozil and CYP2C8 substrates (Backman et al., 2002;
Jaakkola et al., 2005; Tornio et al., 2014; Itkonen et al., 2016, 2018,
2019), no significant correlations were observed between the plasma
concentrations of clopidogrel acyl-b-D-glucuronide or gemfibrozil 1-O-
glucuronide and changes in desloratadine pharmacokinetics.
Discussion
Recently, CYP2C8 was suggested to have an essential role in
the biotransformation of desloratadine to its major metabolite, 3-
hydroxydesloratadine (Kazmi et al., 2015a). Clopidogrel and gemfi-
brozil are both clinically relevant CYP2C8 inhibitors, but previously
their CYP2C8 inhibition potency had not been comparedwith each other
in humans. In addition, selective, sensitive, and safe CYP2C8 probe
substrates are required for DDI studies. For example, repaglinide, the
CYP2C8 probe drug recommended by FDA (https://www.fda.gov/
downloads/drugs/guidances/ucm292362.pdf), has also other disposi-
tion mechanisms, e.g., organic anion-transporting polypeptide 1B1
(OATP1B1)-mediated active hepatic uptake andmetabolismbyCYP3A4
(Tornio et al., 2012), which can complicate data interpretation. For these
reasons, we conducted a clinical study in healthy volunteers to investigate
the role of CYP2C8 in desloratadine metabolism, and to compare the
CYP2C8 inhibitory properties of clopidogrel and gemfibrozil. Overall,
both clopidogrel and gemfibrozil increased the exposure to desloratadine
and radically reduced the concentrations of 3-hydroxydesloratadine.
TABLE 1
Pharmacokinetic variables of desloratadine, 3-hydroxydesloratadine, and 3-hydroxydesloratadine-O-glucuronide in 11 healthy subjects who ingested placebo, clopidogrel
(300 mg on day 3, and 75 mg on days 4 and 5), or gemfibrozil (600 mg BID for 5 days). On day 3 of each study phase, a single 5 mg dose of desloratadine was administered
1 hour after pretreatment.
Data are given as geometric mean with geometric coefficient of variation (in brackets), except for tmax, which is given as median with range. The geometric mean ratios between the clopidogrel and















Phase Ratio (90% CI)
Desloratadine
Cmax (ng/ml) 2.83 (43) 4.65 (28) 1.65 (1.33–2.04)*** 4.93 (34) 1.74 (1.37–2.21)*** 1.06 (0.90–1.24); P . 0.9
tmax (h) 4 (1.0–7.0) 4.0 (4.0–7.0) P = 0.4 4.0 (3.0–7.0) P . 0.9 P . 0.9
t1/2 (h) 17 (19) 26 (18) 1.5 (1.3–1.8)*** 39 (19) 2.2 (2.0–2.5)*** 1.5 (1.2–1.8)†††
AUC0–71h (ng  h/ml) 44.3 (55) 111 (32) 2.51 (2.05–3.07)*** 156 (27) 3.51 (2.67–4.63)*** 1.40 (1.24–1.59)†††
AUC0–‘ (ng  h/ml) 46.8 (56) 131 (36) 2.80 (2.32–3.38)*** 216 (28) 4.62 (3.46–6.16)*** 1.65 (1.42–1.91)†††
3-Hydroxydesloratadine
Cmax (ng/ml) 1.29 (24) 0.388 (34) 0.30 (0.25–0.37)*** 0.05 (42) 0.04 (0.03–0.05)*** 0.13 (0.10–0.17)†††
tmax (h) 4.0 (4.0–7.0) 4.0 (4.0–11.0) P = 0.2 11.0 (7.0–11.0) P = 0.009 P = 0.021
t1/2 (h) 25 (13) 51 (40) 2.0 (1.7–2.4)*** N/A — —
AUC0–71h (ng  h/ml) 29.5 (27) 15.4 (30) 0.52 (0.44–0.62)*** 1.81 (54) 0.06 (0.04–0.09)*** 0.12 (0.09–0.16)†††




0.666 (53) 0.139 (47) 0.21 (0.18–0.24)*** 0.012 (70) 0.017 (0.013–0.024)*** 0.08 (0.07–0.11)†††
3-Hydroxydesloratadine-O-glucuronide
Cmax (ng/ml) 35.0 (40) 13.0 (34) 0.37 (0.31–0.45)*** 1.32 (54) 0.04 (0.02–0.06)*** 0.10 (0.07–0.15)†††
tmax (h) 9.0 (7.0–11.0) 9.0 (7.0–11) P = 0.9 11.0 (11.0–23.0) P = 0.03 P = 0.048
t1/2 (h) 19 (18) 35 (36) 1.9 (1.6–2.2)*** N/A — —
AUC0–71h (ng  h/ml) 863 (32) 475 (25) 0.55 (0.46–0.65)*** 54.5 (47) 0.06 (0.04–0.10)*** 0.11 (0.09–0.15†††
AUC0–‘ (ng  h/ml) 940 (32) 666 (18) 0.71 (0.62–0.81)*** N/A — —
N/A, not applicable.
***P , 0.001 vs. placebo phase, †††P , 0.001 vs. clopidogrel phase.












On the basis of in vitro results, Kazmi et al. (2015a) suggested an
unusual metabolic pathway, by which three distinct consecutive metabolic
steps are required for the formation of 3-hydroxydesloratadine (Fig. 1).
First, uridine 59-diphospho-glucuronosyltransferase (UGT) 2B10 metabo-
lizes desloratadine to its N-glucuronide. Subsequently, the N-glucuronide
undergoes rapid oxidation to 3-hydroxydesloratadine-N-glucuronide
very selectively byCYP2C8 (Kazmi et al., 2015a). Finally, the glucuronide
moiety is deconjugated, most probably spontaneously, during or very
shortly after the CYP2C8-mediated 3-hydroxylation (Kazmi et al., 2015a).
The resulting 3-hydroxydesloratadine is further conjugated to O-
glucuronide by UGT1A1, UGT1A3, andUGT2B15 (Ghosal et al., 2004).
The investigators were unable to detect desloratadine-N-glucuronide,
most probably owing to its instability and rapid CYP2C8-mediated
oxidation (Kazmi et al., 2015a). Although desloratadine-N-glucuronide
was undetectable in the experiments, desloratadine was not 3-hydroxylated
by CYP2C8 unless coincubated with UGT2B10, and thus the proposed
pathway seems convincing (Kazmi et al., 2015a). Of note, desloratadine
is also biotransformed to 5-hydroxy and 6-hydroxy metabolites by several
P450 enzymes, namely CYP3A4, CYP2D6, and CYP2C19, in vitro
(Barecki et al., 2001; McClellan and Jarvis, 2001; Kazmi et al., 2015b).
However, these are only minor elimination pathways, and inhibition of
these enzymes does not lead to clinically relevant changes in deslor-
atadine pharmacokinetics in vivo (Henz, 2001; McClellan and Jarvis,
2001). Furthermore, the CYP3A4 and OATP1B1 inhibitor erythromycin
did not significantly increase desloratadine exposure, suggesting lack of
OATP1B1 contribution in desloratadine disposition (Henz, 2001).
In the clopidogrel phase of the present study, the AUCs of 3-
hydroxydesloratadine and itsO-glucuronide were markedly decreased,
whereas the AUC of parent desloratadine was more than doubled. The
resulting reduction in 3-hydroxydesloratadine:desloratadine AUC0–71 h
ratio by clopidogrel is consistent with an average 80% inhibition of
CYP2C8 activity, assuming that clopidogrel had no effect on non-
CYP2C8-mediated metabolism of desloratadine N-glucuronide nor
on hydrolysis of either of the N-glucuronide intermediates. With
respect to clopidogrel’s CYP2C8 inhibition potency, this estimate is
in accordance with recent findings that clopidogrel causes about 5-fold
increases in exposures to repaglinide and dasabuvir, which are among
the most sensitive CYP2C8 substrates identified so far (Tornio et al.,
2014; Itkonen et al., 2019).
In most individuals, gemfibrozil almost abolished 3-hydroxydeslor-
atadine and its O-glucuronide from plasma, while reducing the
3-hydroxydesloratadine:desloratadine AUC0–71h ratio to less than 2% of
that during the placebo phase (Fig. 3A; Table 1). In addition, gemfibrozil
increased desloratadine exposure in all subjects. Concerning the CYP2C8-
inhibitory strength of gemfibrozil, the deductions inferred from the current
results are highly concordant with the estimates from previous studies with
gemfibrozil and the CYP2C8 substrate repaglinide, which indicated that
clinical doses of gemfibrozil (600 mg BID) decrease CYP2C8 activity
by .98% (Honkalammi et al., 2012).
The effects of gemfibrozil on desloratadine pharmacokinetics resem-
bled those of clopidogrel but were significantly more prominent, which
is in line with the static predictions made on the basis of the unbound
plasma Cmax of gemfibrozil and clopidogrel glucuronides, and their
in vitro mechanism-based inhibition parameters reported in the literature
(Fig. 3F). The AUC of desloratadine was augmented 2.8-fold (range 1.8-
to 4.7-fold) and 4.6-fold (range 2.3- to 7.9-fold) by clopidogrel and
gemfibrozil, respectively. The increases in desloratadine AUC caused
by clopidogrel and gemfibrozil correlated with each other (Fig. 3C), and
with the 3-hydroxydesloratadine:desloratadine AUC0–71 h ratio in the
placebo phase that probably reflects CYP2C8 activity at baseline
(Fig. 3, D and E). These findings suggest that the basis of the effects
of clopidogrel and gemfibrozil is a shared CYP2C8-selective mecha-
nism and that interindividual variation in CYP2C8 enzyme activity
largely explains the variability in sensitivity of desloratadine to CYP2C8
inhibition. The present and previous reports imply that clinical doses of
gemfibrozil cause stronger interactions with CYP2C8 substrates than
those of clopidogrel, thus revealing more sensitively whether CYP2C8
participates in the metabolism of the victim drug (Table 3). However,
gemfibrozil also inhibits the activity of certain membrane transporters,
most notably hepatic OATP1B1 (Neuvonen et al., 2006; Tornio et al.,
2017), which in turn is not inhibited by clopidogrel to a clinically relevant
extent (Itkonen et al., 2015; Kim et al., 2016). Therefore, interpreting the
DDI mechanisms can be challenging when gemfibrozil 600 mg BID is
used as a model CYP2C8 inhibitor, if the victim drug is also a substrate of
OATP1B1, as repaglinide and cerivastatin are (Backman et al., 2002,
2016; Niemi et al., 2003; Shitara et al., 2003; Niemi et al., 2005; Ogilvie
et al., 2006; Tornio et al., 2017). In such cases, clopidogrel could be
considered as an alternative model inhibitor.
Our current results imply that the metabolism of desloratadine to its
3-hydroxymetabolite is highly dependent onCYP2C8 activity in humans
in vivo. Although gemfibrozil and clopidogrel increased the AUC of
desloratadine less than they had increased the AUCs of repaglinide and
dasabuvir (Table 3), the 3-hydroxydesloratadine:desloratadine ratio
seemed to be highly sensitive to CYP2C8 inhibition. These observa-
tions corroborate the previous in vitro findings of Kazmi et al. (2015a)
and suggest the possibility of using desloratadine as a CYP2C8 probe
substrate. However, an important caveat is that the formation of
3-hydroxydesloratadine is also dependent on UGT2B10 activity
(Kazmi et al., 2015b) and can probably be altered by inhibition and
induction of UGT2B10. Of note, neither clopidogrel nor gemfibrozil is
TABLE 2
Pharmacokinetic variables of clopidogrel, clopidogrel active cis-5-thiol metabolite,
clopidogrel carboxylic acid, clopidogrel acyl-b-D-glucuronide, gemfibrozil, and
gemfibrozil 1-O-glucuronide in 11 healthy volunteers after clopidogrel 300 mg or
gemfibrozil 600 mg (fifth dose of twice daily dosing) ingested 1 hour before
desloratadine 5 mg.
Data are given as median with range.
Variable Clopidogrel or Gemfibrozil Phase
Clopidogrel
Cmax (ng/ml) 2.88 (0.48–23.2)
tmax (h) 1.5 (0.92–2.0)
t1/2 (h) 3.4 (2.6–10)
AUC0–12 h (ng  h/ml) 11.7 (2.22–40.0)
Clopidogrel active metabolite
Cmax (ng/ml) 23.2 (11.0–41.2)
tmax (h) 0.92 (0.92–1.5)
t1/2 (h) 1.8 (1.3–3.9)
AUC0–12 h (ng  h/ml) 34.6 (16.3–66.0)
Clopidogrel carboxylic acid
Cmax (ng/ml) 9850 (7020–15,800)
tmax (h) 1.5 (0.92–1.5)
t1/2 (h) 4.2 (3.1–8.0)
AUC0–12 h (ng  h/ml) 35,400 (38,900–92,100)
Clopidogrel acyl-b-D-glucuronide
Cmax (ng/ml) 3980 (1750–7390)
tmax (h) 2.0 (1.5–3.0)
t1/2 (h) 3.3 (2.7–4.0)
AUC0–12 h (ng  h/ml) 14,400 (10,900–35,800)
Gemfibrozil
Cmax (mg/ml) 18.1 (14.3–29.1)
tmax (h) 2.0 (1.5–4.0)
t1/2 (h) 2.3 (1.7–2.7)
AUC0–12 h (mg  h/ml) 75.7 (56.5–130)
Gemfibrozil 1-O-glucuronide
Cmax (mg/ml) 14.5 (10.2–20.3)
tmax (h) 3.0 (1.5–6.0)
t1/2 (h) 2.5 (1.7–3.4)
AUC0–12 h (mg  h/ml) 80.0 (46.2–147)












Fig. 3. The individual change in 3-hydroxydesloratadine:desloratadine area under the plasma concentration time curve (AUC0–71 h) ratio (A) and desloratadine AUC0–‘ (B)
in the clopidogrel and gemfibrozil phase in comparison with placebo phase value. The correlation of desloratadine AUC0–‘ ratio between gemfibrozil to control and
clopidogrel to control (C), and the correlation of 3-hydroxydesloratadine:desloratadine AUC0–71 h ratio in the placebo phase with desloratadine AUC0–‘ clopidogrel to
control ratio (D), and desloratadine AUC0–‘ gemfibrozil to control ratio (E), where the lines depict the linear regression with 95% CI. Predicted CYP2C8 inhibitory effect of
gemfibrozil and clopidogrel using a static prediction equation whose basis was in vitro mechanism-based inhibition parameters of their glucuronide metabolites reported in
the literature and their concentrations at the enzyme site (F). SeeMaterials and Methods for details of the prediction equation. Cmax,u,clop, unbound peak plasma concentration
of clopidogrel acyl-b-D-glucuronide after 300 mg clopidogrel in the current study (0.83 mM with an estimated fraction unbound of 10%); Cmax,u,gemfi, unbound peak plasma
concentration of gemfibrozil 1-O-glucuronide after 600 mg gemfibrozil in the current study (3.9 mM with an estimated fraction unbound of 11.5%).












known to inhibit UGT2B10. Moreover, in some individuals, the t1/2 and
drug exposure of desloratadine are very high, resulting in a “poor
metabolizer” phenotype, which has a population frequency of 17%
in African-Americans and 8% in Native American but is less common
in Caucasians and Hispanics, with a frequency of about 2% (Molimard
et al., 2004; Prenner et al., 2006; Ramanathan et al., 2007). The “poor
metabolizer” phenotype and almost complete CYP2C8 inactivation by
gemfibrozil result in surprisingly similar exposures to desloratadine and
its 3-hydroxy metabolite (Prenner et al., 2006). However, the most
probable explanation for this phenotype is that common UGT2B10
variants prevent the expression of functional UGT2B10 (Berg et al.,
2010a, 2010b; Chen et al., 2010; Murphy et al., 2014; Fowler et al.,
2015). Another possibility for this phenomenon is variability in
CYP2C8, even though nonfunctional alleles in CYP2C8 are rare in
all major populations (Zhou et al., 2017). In any case, individuals
with desloratadine “poor metabolizer” phenotype are probably less
sensitive to changes in desloratadine pharmacokinetics by CYP2C8
inhibitors. Consequently, desloratadine might be suboptimal as a
CYP2C8 probe substrate in, for example, African-Americans. From
another perspective, the good tolerability of desloratadine and its
lack of P450 inhibition could support its usefulness as a CYP2C8
probe substrate (Barecki et al., 2001; Henz, 2001).
As 3-hydroxydesloratadine possesses H1 receptor antagonistic
properties (Murdoch et al., 2003), evaluation of the clinical significance
of the effects of gemfibrozil and clopidogrel on desloratadine pharma-
cokinetics requires consideration of the changes in the concentrations of
both desloratadine and this metabolite. It can be estimated that clopidogrel
roughly doubled and gemfibrozil roughly tripled the sum exposure to
desloratadine and 3-hydroxydesloratadine, which should have no hazard-
ous consequences owing to the large therapeutic index of desloratadine
(Prenner et al., 2006).
As the most probable explanation for the effects of the CYP2C8
inhibitors gemfibrozil and clopidogrel on the pharmacokinetics of
desloratadine is inhibition of CYP2C8-mediated 3-hydroxylation of
a glucuronide metabolite of desloratadine, our results provide clinical
evidence supporting the findings of several in vitro studies that CYP2C8
has the ability to oxidize glucuronide metabolites in humans (Backman
et al., 2016). On the basis of X-ray crystallographic studies, the large
CYP2C8 active site cavity is capable of binding substrates diverse in
structure (Schoch et al., 2008). As demonstrated in molecular docking
simulations, there is a hydrophilic region in the active site that can
accommodate the glucuronide moiety of certain metabolites, including
clopidogrel acyl-b-D-glucuronide and gemfibrozil 1-O-glucuronide (Baer
et al., 2009; Tornio et al., 2014; Backman et al., 2016), in contrast to most
other P450 enzymes. Accordingly, molecular modeling combined with
in vitro experiments provide useful means to predict CYP2C8-involved
DDI potential of drugs and their metabolites.
In conclusion, our clinical study revealed two DDIs with interesting
characteristics and implications. First, in the clopidogrel-desloratadine
and gemfibrozil-desloratadine interactions, both the perpetrator and victim
compounds are glucuronide metabolites, highlighting the need to consider
the properties of xenobiotic glucuronides with respect to evaluation of the
risk of pharmacokinetic DDIs. Second, despite its complex metabolism,
desloratadine could serve as a safe CYP2C8 probe substrate in clinical
DDI studies owing to the CYP2C8-dependent 3-hydroxydesloratadine
formation. It could be especially useful if the perpetrator also inhibits
CYP3A4 or OATP1B1, because it differs from other recommended
CYP2C8 probe substrates that are also dependent on CYP3A4 and
OATP1B1. However, the suggested sequential metabolism and obligatory
role of UGT2B10 prior to CYP2C8-mediated oxidation of desloratadine
(Kazmi et al., 2015a) may complicate its DDI interpretation. Therefore,
the applicability of desloratadine in populations with a high prevalence
TABLE 3
A comparison of the fold-changes (R) in pharmacokinetic parameters of CYP2C8 substrates (given in single doses) caused by gemfibrozil and clopidogrel in the present
study and previous publications
Data are either arithmetic or geometric mean ratios with 90% or 95% confidence intervals (CI), or ranges.
Victim Drug
and Its Dose
Clopidogrel 300 mg followed by 75 mg QD Ratio (R) to Placebo (90% or 95% CI, or
range)
Gemfibrozil 600 mg BID Ratio (R) to Placebo (90% or 95% CI, or Range)
AUC0–‘R CmaxR Reference AUC0–‘R CmaxR Reference
Dasabuvir
250 mg 4.7 (90% CI = 3.2–6.7) 1.6 (90% CI = 1.0–2.6) Itkonen et al.
(2019)
11.3 (90% CI = 9.1–14) 2.0 (90% CI = 1.7–2.4) Menon et al. (2015)
Desloratadine
5 mg 2.8 (90% CI = 2.3–3.4) 1.7 (90% CI = 1.3–2.0) Present study 4.6 (90% CI = 3.5–6.2) 1.7 (90% CI = 1.4–2.2) Present study
Montelukast
10 mg 2.0 (90% CI = 1.7–2.3) 1.0 (90% CI = 0.8–1.2) Itkonen et al.
(2018)
4.4 (95% CI = 3.8–5.0) 1.5 (95% CI = 1.3–1.8) Karonen et al. (2010)
4.3 (95% CI = 2.9–6.3) 1.5 (95% CI = 0.9–2.3) Karonen et al.(2012)
Pioglitazone
1 mg 2.0 (95% CI = 1.6–2.5)a Not reported Kim et al. (2016)
15 mg 2.1 (90% CI = 1.8–2.6) 1.0 (90% CI = 0.8–1.4) Itkonen et al.
(2016)
3.2 (Range = 2.3–6.5) 1.1 (Range = 0.5–2.6) Jaakkola et al. (2005)
30 mg 3.4 (Range = 2.3–6.2) Not reported Deng et al.(2005)
Repaglinide
0.1 mg 3.1 (95% CI = 2.1–4.1)b Not reported Kim et al. (2016)
0.25 mg 5.1 (90% CI = 3.9–6.6) 2.5 (90% CI = 1.8–3.5) Tornio et al.
(2014)
8.1 (Range = 5.5–15) 2.4 (Range = 1.7–6.1) Niemi et al. (2003)
3.9 (90% CI = 2.9–5.3)c 2.0 (90% CI = 1.3–3.1)c Tornio et al.
(2014)
7.0 (Range = 2.9–14) 2.2 (Range = 1.4–2.9) Tornio et al. (2008)
7.6 (Range = 4.2–12) 2.7 (Range = 1.5–3.7) Backman et al. (2009)
7.0 (90% CI = 6.0–8.1) 2.0 (90% CI = 1.6–2.5) Honkalammi et al.
(2012)
AUC0–8h, area under the plasma concentration –time curve from 0 to 8 hours; AUC0–24h, area under the plasma concentration–time curve from 0 to 24 hours; AUC0–‘, area under the plasma
concentration–time curve from time 0 to infinity.
aAUC0–24 h ratio.
bAUC0–8 h ratio.
cEffect on day 3 of treatment with clopidogrel 300 mg on day 1 followed by 75 mg QD.












of desloratadine “poor metabolizer” phenotype requires further studies.
Last, our study confirms that gemfibrozil is a stronger CYP2C8 inhibitor
than clopidogrel, but they both can be used asmodel CYP2C8 inhibitors,
as long as their DDI profile is taken into account in the study design and
interpretation.
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